Trial Search Results

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

The goal of this study is to develop a non-invasive imaging test for in vivo detection of kidney transplant rejection. The hypotheses are that 1) Ferumoxytol-MRI can generate accurate estimates of tissue iron concentrations and tissue macrophages. 2) The signal given by a renal allograft on Ferumoxytol-MRI demonstrates significant differences between rejected and non-rejected transplants.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Lucile Packard Children's Hospital

Stanford Investigator(s):

Intervention(s):

  • Drug: Feraheme
  • Other: MRI-GE Healthcare 3 Tesla magnet

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Completed solid organ transplant with referral for transplant follow-up

Exclusion Criteria:

   - Exclusion criteria comprise MR-incompatible metal implants, need of sedation (since an
   anesthesia is not supported by this), claustrophobia or hemosiderosis/hemochromatosis.

Ages Eligible for Study

8 Years - 40 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Anne Sawyer
650-302-2846
Recruiting